Real‐world use of lecanemab: patient pathway findings from a US multicenter study

Documenti analoghi

• Real‐World Insights on the Lecanemab Patient Pathway in Early Alzheimer’s Disease in the United States
  di: Michael Henry Rosenbloom, et al.
  Pubblicazione: (2025)
• Blood‐Based Biomarkers in the Lecanemab Patient Pathway for Early Alzheimer’s Disease in the United States
  di: Cara Leahy, et al.
  Pubblicazione: (2025)
• Real‐World Use of Lecanemab in APOE ε4 Homozygotes and in Patients on Antithrombotic Therapy
  di: Marwan N. Sabbagh, et al.
  Pubblicazione: (2025)
• Real‐World Use of Lecanemab in Patients With Early Alzheimer’s Disease in the United States: a Case Series Review
  di: David C Weisman, et al.
  Pubblicazione: (2025)
• Real‐world experience with lecanemab therapy for Alzheimer's disease in the Intermountain West
  di: Bethany C. Curd, et al.
  Pubblicazione: (2026)